Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934606 · ClinicalTrials.gov registry record
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 1,488
- Enrollment target
NCT03934606 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,488 participants.
The verdict
NCT03934606 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 1,488 participants
- Enrollment target
Study Summary
To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.
Interventions
- BEHAVIORAL Genetic testing for hereditary predisposition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,488 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2025-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934606
The ClinicalTrials.gov registry entry for NCT03934606 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genetic testing for hereditary predisposition is the first listed.
NCT03934606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934606 about?
NCT03934606 is a clinical study titled "Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model". To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study...
What is the current status of trial NCT03934606?
This trial is currently completed. The enrollment target is 1,488 participants. The study started on 2018-01-01. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT03934606?
The interventions under investigation include: Genetic testing for hereditary predisposition (BEHAVIORAL).
Who is sponsoring clinical trial NCT03934606?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.